Correlation
The correlation between SNY and NVS is 0.46, which is considered to be moderate. This suggests that the two assets have some degree of positive relationship in their price movements. Moderate correlation can be acceptable for portfolio diversification, offering a balance between risk and potential returns.
SNY vs. NVS
Compare and contrast key facts about Sanofi (SNY) and Novartis AG (NVS).
Scroll down to visually compare performance, riskiness, drawdowns, and other indicators and decide which better suits your portfolio: SNY or NVS.
Performance
SNY vs. NVS - Performance Comparison
Loading data...
Key characteristics
SNY:
0.32
NVS:
0.95
SNY:
0.62
NVS:
1.43
SNY:
1.07
NVS:
1.20
SNY:
0.35
NVS:
1.02
SNY:
0.78
NVS:
2.18
SNY:
9.73%
NVS:
9.32%
SNY:
24.80%
NVS:
20.20%
SNY:
-46.65%
NVS:
-41.72%
SNY:
-13.23%
NVS:
-0.80%
Fundamentals
SNY:
$127.76B
NVS:
$222.36B
SNY:
$2.83
NVS:
$6.38
SNY:
18.50
NVS:
17.65
SNY:
0.85
NVS:
1.31
SNY:
2.83
NVS:
4.18
SNY:
1.52
NVS:
5.80
SNY:
$43.77B
NVS:
$52.86B
SNY:
$31.12B
NVS:
$39.86B
SNY:
$9.61B
NVS:
$21.88B
Returns By Period
In the year-to-date period, SNY achieves a 6.90% return, which is significantly lower than NVS's 23.24% return. Over the past 10 years, SNY has underperformed NVS with an annualized return of 3.99%, while NVS has yielded a comparatively higher 7.13% annualized return.
SNY
6.90%
-6.17%
6.33%
7.79%
1.60%
4.17%
3.99%
NVS
23.24%
2.00%
13.39%
19.09%
14.81%
11.38%
7.13%
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Risk-Adjusted Performance
SNY vs. NVS — Risk-Adjusted Performance Rank
SNY
NVS
SNY vs. NVS - Risk-Adjusted Performance Comparison
This table presents a comparison of risk-adjusted performance metrics for Sanofi (SNY) and Novartis AG (NVS). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Loading data...
Dividends
SNY vs. NVS - Dividend Comparison
SNY's dividend yield for the trailing twelve months is around 4.48%, more than NVS's 3.45% yield.
| TTM | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
SNY Sanofi | 4.48% | 4.22% | 3.83% | 4.22% | 3.80% | 3.61% | 3.46% | 4.29% | 3.67% | 4.03% | 3.79% | 4.19% |
NVS Novartis AG | 3.45% | 3.84% | 3.44% | 3.91% | 4.08% | 3.40% | 2.87% | 3.72% | 3.50% | 4.06% | 3.51% | 3.14% |
Drawdowns
SNY vs. NVS - Drawdown Comparison
The maximum SNY drawdown since its inception was -46.65%, which is greater than NVS's maximum drawdown of -41.72%. Use the drawdown chart below to compare losses from any high point for SNY and NVS.
Loading data...
Volatility
SNY vs. NVS - Volatility Comparison
Sanofi (SNY) has a higher volatility of 9.44% compared to Novartis AG (NVS) at 7.47%. This indicates that SNY's price experiences larger fluctuations and is considered to be riskier than NVS based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading data...
Financials
SNY vs. NVS - Financials Comparison
This section allows you to compare key financial metrics between Sanofi and Novartis AG. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
SNY vs. NVS - Profitability Comparison
SNY - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on May 2025, Sanofi reported a gross profit of 7.72B and revenue of 10.61B. Therefore, the gross margin over that period was 72.8%.
NVS - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on May 2025, Novartis AG reported a gross profit of 10.39B and revenue of 13.62B. Therefore, the gross margin over that period was 76.3%.
SNY - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on May 2025, Sanofi reported an operating income of 2.29B and revenue of 10.61B, resulting in an operating margin of 21.5%.
NVS - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on May 2025, Novartis AG reported an operating income of 4.66B and revenue of 13.62B, resulting in an operating margin of 34.2%.
SNY - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on May 2025, Sanofi reported a net income of 1.87B and revenue of 10.61B, resulting in a net margin of 17.7%.
NVS - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on May 2025, Novartis AG reported a net income of 3.61B and revenue of 13.62B, resulting in a net margin of 26.5%.